Diabetes affects more than half a billion people worldwide and is driven by the loss or dysfunction of insulin‑producing pancreatic β‑cells. Here, stem cell–derived islets offer a promising path towards new therapies and improved drug development, but reliably assessing their functional quality has remained a major bottleneck.
A new study led by Matthias Meier and Heiko Lickert, recently published in Biosensors and Bioelectornics, has now introduced a novel bioelectronic platform that enables real‑time, non‑invasive monitoring of insulin secretion from individual stem cell-derived islets. The approach combines impedance spectroscopy with microcavity microelectrode arrays, allowing to directly track functional responses to glucose stimulation in three‑dimensional islet‑like tissues.
Unlike conventional insulin secretion assays, which are labor‑intensive, destructive, and limited to endpoint measurements, the new method captures dynamic functional activity at high temporal resolution. In the study, glucose stimulation triggered characteristic electrical impedance changes that closely correlated with insulin release measured by established biochemical assays. When β‑cell activity was pharmacologically inhibited, both insulin secretion and the electrical signals were strongly reduced, confirming the specificity of the readout.
A key advantage of the platform is its ability to resolve functional differences between individual islet clusters and even within single clusters, thereby revealing a considerable heterogeneity that is masked by pooled measurements. As such, the platform enables a much more precise assessment of islet quality and maturation.
Importantly, our study complements a conceptually similar single‑cell electrophysiology study in cyborg pancreatic organoids published in Science by providing a scalable, non‑invasive readout of insulin secretion at the level of intact islet clusters. While the cyborg platform resolves how α‑ and β‑cell electrical programs emerge and synchronize during maturation, our impedance‑based approach links these cellular dynamics to tissue‑level hormone output, enabling functional screening across many stem cell–derived islets.
By providing such a fast, scalable, and label‑free tool for functional screening, our technology opens new possibilities for optimizing stem cell differentiation protocols, accelerating anti‑diabetic drug discovery, and developing robust potency assays for future cell‑based therapies. In the long term, the platform could help bridge a critical gap on the path toward clinical translation of stem cell–derived β‑cell replacement strategies.